Soft Tissue Sarcoma Market

DelveInsight’s ‘Soft Tissue Sarcoma Market Insights, Epidemiology, and Market Forecast-2030’ report deliver an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Soft Tissue Sarcoma (STS) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.  


The Soft Tissue Sarcoma market report provides analysis regarding current treatment practices, emerging drugs like AL3818, Fibromun, AL3818, Ripretinib, market share of the individual therapies, historical, current and forecasted Soft Tissue Sarcoma market Size from 2017 to 2030 segmented by seven major markets.


 The Report also covers current Soft Tissue Sarcoma treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.


Geography Covered

  • The United States
  •  EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  •  Japan


Study Period: 2017–2030


Soft Tissue Sarcoma - Disease Understanding and Treatment Algorithm


Soft Tissue Sarcoma Overview

Soft-tissue sarcoma are rare neoplasms that can develop in supporting or connective tissue, such as the muscle, nerves, tendons, blood vessels, and fatty and fibrous tissues. They commonly affect the arms, legs, and trunk. They also appear in the stomach and intestines (GIST) as well as behind the abdomen (retroperitoneal sarcomas) and the female reproductive system (gynecological sarcomas). STSs may be classified according to the involved cell-type, the specific nature of the malignancy, and the disease’s clinical course.


According to the World Health Organization (WHO), there are more than 50 histologic subtypes of STSs. The signs and symptoms of STSs vary greatly from patients to patients based on the type of STS. However, it is not associated with any noticeable symptoms early in the course of the disease, but the affected individuals may notice slow-growing, painless mass in the affected area.


Soft Tissue Sarcoma Treatment 

This chapter covers the details of conventional and current medical therapies available in the Soft tissue sarcoma market for the treatment of the condition. It also provides the country-wise Soft Tissue Sarcoma treatment guidelines and algorithm across the United States, Europe and Japan. 

DelveInsight’s Soft tissue sarcoma market report gives a thorough understanding of the disease by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides Soft tissue sarcoma treatment algorithms and treatment guidelines in the US, Europe, and Japan.


Soft Tissue Sarcoma Epidemiology

The Soft Tissue Sarcoma epidemiology chapters provide insights about historical and current Soft Tissue Sarcoma patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. Soft tissue sarcoma epidemiology is segmented by gender-specific incidence, type-specific incidence, age-specific, stage-specific, and extremities. The report includes thorough analysis of all segmentations.


Soft Tissue Sarcoma has various subtypes. It was observed that in the United States and European countries, liposarcoma and leiomyosarcoma were the most incident subtypes of STS, which contributed to the majority of the cases. Whereas in Japan, subtypes, fibroblastic sarcomas and liposarcoma were more common.


According to DelveInsight’s, the total Soft Tissue Sarcoma incident population in seven major markets was 40,155 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017–2030).


Among all the seven major markets, the United States accounts for the highest number of Soft Tissue Sarcoma cases. In 2017, there were 12,390 incident cases of STS—which did not include GIST cases—in the United States. The total incident cases of GIST which were observed in the United States in 2017 accounted for 5,090. This lead to the total Soft Tissue Sarcoma incident population to 17,480 in 2017.


Soft tissue sarcoma market

Soft Tissue Sarcoma Drug Chapters

Drug chapter segment of the Soft Tissue Sarcoma report encloses the detailed analysis of Soft Tissue Sarcoma marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Soft Tissue Sarcoma clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

The report provides the details of the emerging therapies under the late and mid-stage of development for Soft Tissue Sarcoma treatment and marketed product available for Soft Tissue Sarcoma treatment.


 STS primarily encountered in adults but can affect patients of any age. There are many histologic subtypes, and the malignancy can be low or high grade. Soft tissue sarcoma treatments may include surgery, chemotherapy, radiation therapy, or a combination of these therapies.

The emerging therapies are classified into four categories based on their line of therapy. The upcoming first-line therapies that are going to be launched in the forecasted period includes, AL3818 (anlotinib) and Fibromun. The second-line emerging therapies include Vigil in combination with irinotecan and temozolomide, AL3818, GSK 3377794, Ripretinib (DCC-2618), Tazemetostat, Abemaciclib, Pembrolizumab, Crizotinib, ABI-009, and SRA737. The third-line emerging therapies include Avapritinib, Cabozantinib, and Selinexor. The fourth-line emerging therapies include Avapritinib, TAS-116, Crenolanib, and Ripretinib.


Soft Tissue Sarcoma Market Outlook

The Soft Tissue Sarcoma market size is expected to increase at a significant CAGR during the study period (2017–2030). Among all the seven major markets, the United States accounts for the highest Soft Tissue Sarcoma market size. Among EU5, Germany had the highest Soft Tissue Sarcoma market size in 2017 USD 22.06 million, followed by Italy. The market size of STS (excluding GIST) in Japan was found to be least in 2017.

The key companies involved for Soft Tissue Sarcoma market treatment are Amgen, BioPharma, AstraZeneca and many others.



Soft Tissue Sarcoma Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Soft Tissue Sarcoma market or expected to get launched in the market during the study period 2017-2030. The analysis covers Soft Tissue Sarcoma market uptake by drugs; patient uptake by therapies; and sales of each drug.


This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The current Soft Tissue Sarcoma market size is mainly attributed to Votrient, Yondelis, Halaven, and various anthracycline and non-anthracycline regimens. The market size of GIST in the United States was found to be USD 119.7 million in 2017 and expected to increase during the forecast period (2020–2030) due to potential therapies Vitrakvi, Rozlytrek, Avapritinib, Ripretinib and others   


Soft Tissue Sarcoma Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Soft Tissue Sarcoma key players involved in developing targeted therapeutics.


Pipeline Development Activities

The report covers the detailed information of Soft Tissue Sarcoma collaborations, acquisition and merger, licensing, patent details and other information for Soft Tissue Sarcoma emerging therapies.


Reimbursement Scenario in Soft Tissue Sarcoma

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.


KOL- Views 

To keep up with current market trends, we take KOLs and SME's opinion working in Soft Tissue Sarcoma domain through primary research to fill the data gaps and validate our secondary research. We have interviewed orthopaedician, oncologist, and other industry experts to cull their opinion to understand and validate current and emerging therapies treatment patterns or Soft Tissue Sarcoma market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs. 


Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Soft Tissue Sarcoma Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.


Report Highlights

  • In the coming years, Soft Tissue Sarcoma market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the Soft Tissue Sarcoma market size to enable the drug manufacturers to penetrate more into the market
  • Major players like Blueprint Medicines Corporation, Gradalis, Karyopharm Therapeutics and many others are involved in developing therapies for Soft Tissue Sarcoma. Launch of emerging therapies will significantly impact the Soft Tissue Sarcoma market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Soft Tissue Sarcoma
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities


Soft Tissue Sarcoma Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Soft Tissue Sarcoma Pipeline Analysis
  • Soft Tissue Sarcoma Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies


Soft Tissue Sarcoma Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage 
  • Soft Tissue Sarcoma Epidemiology Segmentation
  • Key Cross Competition 
  • Highly Analyzed Market
  • Drugs Uptake


Soft Tissue Sarcoma Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers


Key Questions

Market Insights:

  • What was the Soft Tissue Sarcoma market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Soft Tissue Sarcoma total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Soft Tissue Sarcoma market size during the forecast period (2017-2030)?
  • At what CAGR, the Soft Tissue Sarcoma market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Soft Tissue Sarcoma market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Soft Tissue Sarcoma market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?


Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Soft Tissue Sarcoma?
  • What is the historical Soft Tissue Sarcoma patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Soft Tissue Sarcoma in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Soft Tissue Sarcoma?
  • Out of all 7MM countries, which country would have the highest prevalent population of Soft Tissue Sarcoma during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?


Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the Soft Tissue Sarcoma treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Soft Tissue Sarcoma in the USA, Europe, and Japan?
  • What are the Soft Tissue Sarcoma marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Soft Tissue Sarcoma?
  • How many therapies are developed by each company for Soft Tissue Sarcoma treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Soft Tissue Sarcoma treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Soft Tissue Sarcoma therapies? 
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies? 
  • What are the clinical studies going on for Soft Tissue Sarcoma and their status?
  • What are the key designations that have been granted for the emerging therapies for Soft Tissue Sarcoma?
  • What are the global historical and forecasted market of Soft Tissue Sarcoma?


Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Soft Tissue Sarcoma market
  • To understand the future market competition in the Soft Tissue Sarcoma market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Soft Tissue Sarcoma in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Soft Tissue Sarcoma market
  • To understand the future market competition in the Soft Tissue Sarcoma market


At what CAGR, Soft Tissue Sarcoma market is expected to grow for the study period 2017-30?

The Soft Tissue Sarcoma market is expected to increase at a CAGR of 6.47% during forecast period (2017-2030). 


Which geography accounted for the largest Soft Tissue Sarcoma market size?

United States accounted for the largest Soft Tissue Sarcoma market size.


What is forecasted soft tissue sarcoma market size in 2030?

DelveInsight estimates an increase in STS Market Size during the study period, 2017–2030


What are the present Soft Tissue Sarcoma market drivers?

Competitive Landscape, Precision Medicine Approach & Novel Therapies for Subtype of STS.


What are the Soft Tissue Sarcoma market barriers?

High Cost of Treatment, Stringent Government Regulations & High Failure Rate in the Clinical Trials.


How many companies are developing drugs for soft tissue sarcoma?

Currently more than 8 companies are developing drugs for soft tissue sarcoma.


Which are the leading companies in soft tissue sarcoma market?

Key Companies - Bayer, Gradalis, Karyopharm, Novartis, Eli Lilly, GlaxoSmithKline, Merck Sharp& Dohme Corp. and several others.


How is epidemiology segmented for soft tissue sarcoma?

Total Incident Cases of STS in the 7MM, Gender-Specific Incidence of STS in the 7MM, Gender-Specific Incidence of STS in the 7MM, Incidence of STS by Extremities (%) in the 7MM, Stage-Specific Incidence of STS in the 7MM and Age-Specific Incidence of STS in the 7MM.

1. Key Insights

2. Executive Summary of Soft-Tissue Sarcoma (STS)

3. Soft-Tissue Sarcomas (STS) Market Overview at a Glance

3.1. Market Share (%) Distribution of Soft-Tissue Sarcomas (STS) in 2017

3.2. Market Share (%) Distribution of Soft-Tissue Sarcomas (STS) in 2030

4. Soft-Tissue Sarcomas (STS): Disease Background and Overview

4.1. Introduction

4.2. Types of Soft-Tissue Sarcomas (STS)

4.3. The Molecular Biology of Soft-Tissue Sarcomas (STS)

4.4. Stages of Soft-Tissue Sarcomas (STS)

4.5. Diagnosis of Soft-Tissue Sarcomas (STS)

4.5.1. Medical History and Physical Exam

4.5.2. Imaging Tests

4.5.3. Biopsy

4.5.4. Pathological diagnosis of soft tissue sarcomas

4.5.5. Proposed Diagnostic Guidelines

5. Epidemiology and Patient Population

5.1. Key Findings

5.2. Epidemiology and Market Methodology

5.3. 7MM Incident Patient Population of Soft Tissue Sarcoma (STS)

6. Case Reports

6.1. Neo-adjuvant chemotherapy for radiation-associated soft-tissue sarcoma (RAS): A case report

6.2. Soft-Tissue Sarcoma Masquerading as a Hematoma

6.3. Neo-adjuvant chemotherapy for primary sarcoma of the breast: a case report

7. Country Wise-Epidemiology of Soft Tissue Sarcoma (STS)

7.1. United States Epidemiology

7.1.1. Assumptions and Rationale

7.1.2. Total Incident Cases of Soft Tissue Sarcoma (STS) in the United States

7.1.3. Type-Specific Incidence of STS in the United States

7.1.4. Total Incident Cases of Gastrointestinal Stromal Tumor (GIST) in the United States

7.1.5. Total Incident Cases of STS including GIST in the United States

7.1.6. Incidence of STS by Extremities (%) in the United States

7.2. EU5 Epidemiology

7.2.1. Germany

7.2.1.1. Assumptions and Rationale

7.2.1.2. Total Incident Cases of Soft Tissue Sarcoma (STS) in Germany

7.2.1.3. Gender-Specific Incidence of STS in Germany

7.2.1.4. Type-Specific Incidence of STS in Germany

7.2.1.5. Age-Specific Incidence of STS in Germany

7.2.1.6. Stage-Specific Incidence of STS in Germany

7.2.1.7. Incidence of STS by Extremities (%) in Germany

7.2.2. France

7.2.2.1. Assumptions and Rationale

7.2.2.2. Total Incident Cases of Soft Tissue Sarcoma (STS) in France

7.2.2.3. Gender-Specific Incidence of STS in France

7.2.2.4. Type-Specific Incidence of STS in France

7.2.2.5. Age-Specific Incidence of STS in France

7.2.2.6. Stage-Specific Diagnosed Incidence of STS in France

7.2.2.7. Incidence of STS by Extremities (%) in France

7.2.3. Italy

7.2.3.1. Assumptions and Rationale

7.2.3.2. Total Incident Cases of Soft Tissue Sarcoma (STS) in Italy

7.2.3.3. Gender-Specific Incidence of STS in Italy

7.2.3.4. Type-Specific Incidence of STS in Italy

7.2.3.5. Age-Specific Incidence of STS in Italy

7.2.3.6. Stage-Specific Diagnosed Incidence of STS in Italy

7.2.3.7. Incident of STS by Extremities (%) in Italy

7.2.4. Spain

7.2.4.1. Assumptions and Rationale

7.2.4.2. Total Incident Cases of Soft Tissue Sarcoma (STS) in Spain

7.2.4.3. Gender-Specific Incidence of STS in Spain

7.2.4.4. Type-Specific Incidence of STS in Spain

7.2.4.5. Age-Specific Incidence of STS in Spain

7.2.4.6. Stage-Specific Incidence of STS in Spain

7.2.4.7. Incident of STS by Extremities (%) in Spain

7.2.5. United Kingdom

7.2.5.1. Assumptions and Rationale

7.2.5.2. Total Incident Cases of Soft Tissue Sarcoma (STS) in the United Kingdom

7.2.5.3. Gender-Specific Incidence of STS in the United Kingdom

7.2.5.4. Type-Specific Incidence of STS in the United Kingdom

7.2.5.5. Age-Specific Incidence of STS in the United Kingdom

7.2.5.6. Stage-Specific Diagnosed Incidence of STS in the United Kingdom

7.2.5.7. Incident of STS by Extremities (%) in the United Kingdom

7.3. Japan Epidemiology

7.3.1. Assumptions and Rationale

7.3.2. Total Incident Cases of Soft Tissue Sarcoma (STS) in Japan

7.3.3. Gender-Specific Incidence of STS in Japan

7.3.4. Type-Specific Incidence of STS in Japan

7.3.5. Age-Specific Incidence of STS in Japan

7.3.6. Stage-Specific Incidence of STS in Japan

7.3.7. Incident of STS by Extremities (%) in Japan

8. Treatment and Management of Soft Tissue Sarcoma (STS)

8.1. Stage-wise Treatment

8.2. Treatment Algorithms

8.3. Treatment Guidelines

8.3.1. UK guidelines for the management of soft tissue sarcomas

8.3.2. NCCN guidelines for the management of soft tissue sarcomas

8.3.3. Soft Tissue and Visceral Sarcomas: ESMO-EURACAN Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up

9. Unmet Needs

10. Marketed Drugs

10.1. Halaven (Eribulin Mesylate): Eisai

10.1.1. Product Description

10.1.2. Regulatory Milestones

10.1.3. Clinical Development

10.1.4. Ongoing Current Pipeline Activity

10.1.5. Safety and efficacy

10.1.6. Product Profile

10.2. Gleevec (Imatinib Mesylate): Novartis

10.2.1. Product Description

10.2.2. Regulatory Milestones

10.2.3. Clinical Development

10.2.4. Safety and efficacy

10.2.5. Product Profile

10.3. Yondelis (Trabectedin): Pharma Mar

10.3.1. Product Description

10.3.2. Regulatory Milestones

10.3.3. Clinical Development

10.3.4. Safety and efficacy

10.3.5. Product Profile

10.4. Lartruvo (Olaratumab): Eli Lilly

10.4.1. Product Description

10.4.2. Regulatory Milestones

10.4.3. Clinical Development

10.4.4. Safety and efficacy

10.4.5. Product Profile

10.5. Vitrakvi (Larotrectinib; BAY2757556): Bayer/Loxo Oncology

10.5.1. Product Description

10.5.2. Regulatory Milestones

10.5.3. Clinical Development

10.5.4. Safety and efficacy

10.5.5. Product Profile

10.6. Stivarga (Regorafenib): Bayer

10.6.1. Product Description

10.6.2. Regulatory Milestones

10.6.3. Clinical Development

10.6.4. Ongoing Current Pipeline Activity

10.6.5. Safety and efficacy

10.6.6. Product Profile

10.7. Sutent (Sunitinib malate): Pfizer

10.7.1. Product Description

10.7.2. Regulatory Milestones

10.7.3. Clinical Development

10.7.4. Safety and efficacy

10.7.5. Product Profile

10.8. Votrient (Pazopanib): GlaxoSmithKline/Novartis

10.8.1. Product Description

10.8.2. Regulatory Milestones

10.8.3. Clinical Development

10.8.4. Ongoing Current Pipeline Activity

10.8.5. Safety and efficacy

10.8.6. Product Profile

10.9. Vincristine Sulfate: Hospira

10.9.1. Product Description

10.9.2. Regulatory Milestones

10.9.3. Product Profile

10.10. Rozlytrek (Entrectinib): Roche (Genentech)

10.10.1. Product Description

10.10.2. Regulatory Milestones

10.10.3. Safety and Efficacy of Rozlytrek

10.10.4. Clinical trial information

10.10.5. Product Profile

11. Emerging Drugs

11.1. Key Cross Competition

Phase III Emerging Molecules

11.2. Avapritinib (BLU-285): Blueprint Medicines Corporation

11.2.1. Product Description

11.2.2. Other Development Activities

11.2.3. Clinical Development

11.2.4. Clinical Trials Information

11.2.5. Safety and Efficacy

11.2.6. Product Profile

11.3. Vigil (In combination with irinotecan and temozolomide): Gradalis

11.3.1. Product Description

11.3.2. Other Development Activities

11.3.3. Clinical Development

11.3.4. Clinical Trials Information

11.3.5. Safety and Efficacy

11.3.6. Product Profile

11.4. Anlotinib (AL3818): Advenchen Laboratories/Jiangsu Chia-Tai Tianqing Pharmaceutical

11.4.1. Product Description

11.4.2. Other Development Activities

11.4.3. Clinical Development

11.4.4. Clinical Trials Information

11.4.5. Safety and Efficacy

11.4.6. Product Profile

11.5. Selinexor: Karyopharm Therapeutics

11.5.1. Product Description

11.5.2. Other Development Activities

11.5.3. Clinical Development

11.5.4. Clinical Trials Information

11.5.5. Safety and Efficacy

11.5.6. Product Profile

11.6. Aldoxorubicin (INNO-206): CytRx

11.6.1. Product Description

11.6.2. Other Development Activities

11.6.3. Clinical Development

11.6.4. Clinical Trials Information

11.6.5. Safety and Efficacy

11.6.6. Product Profile

11.7. Ripretinib (DCC-2618): Deciphera Pharmaceuticals

11.7.1. Product Description

11.7.2. Other Development Activities

11.7.3. Clinical Development

11.7.4. Clinical Trials Information

11.7.5. Safety and Efficacy

11.7.6. Product Profile

11.8. Fibromun (In combination with Doxorubicin): Philogen

11.8.1. Product Description

11.8.2. Other Development Activities

11.8.3. Clinical Development

11.8.4. Clinical Trials Information

11.8.5. Product Profile

11.9. Hensify (NBTXR3): Nanobiotix

11.9.1. Product Description

11.9.2. Other Development Activities

11.9.3. Clinical Development

11.9.4. Clinical Trials Information

11.9.5. Safety and efficacy

11.9.6. Product Profile

11.10. Crenolanib: Arog Pharmaceuticals

11.10.1. Product Description

11.10.2. Other Development Activities

11.10.3. Clinical Development

11.10.4. Clinical Trials Information

11.10.5. Safety and Efficacy

11.10.6. Product Profile

11.11. TAS-116: Taiho Pharmaceutical

11.11.1. Product Description

11.11.2. Clinical Development

11.11.3. Clinical Trials Information

11.11.4. Safety and Efficacy

11.11.5. Product Profile

Phase II Emerging Molecules

11.12. GSK3377794: GlaxoSmithKline/ Adaptimmune

11.12.1. Product Description

11.12.2. Other Development Activities

11.12.3. Clinical Development

11.12.4. Clinical Trials Information

11.12.5. Safety and Efficacy

11.12.6. Product Profile

11.13. ADP-A2M4: Adaptimmune

11.13.1. Product Description

11.13.2. Other Development Activities

11.13.3. Clinical Development

11.13.4. Clinical Trials Information

11.13.5. Safety and Efficacy

11.13.6. Product Profile

11.14. Tazemetostat (EPZ-6438): Epizyme

11.14.1. Product Description

11.14.2. Other Developmental Activities

11.14.3. Clinical Development

11.14.4. Clinical Trials Information

11.14.5. Safety and Efficacy

11.14.6. Product Profile

11.15. AMG 337: NantPharma/ Amgen

11.15.1. Product Description

11.15.2. Other Development Activities

11.15.3. Clinical Development

11.15.4. Clinical Trials Information

11.15.5. Safety and Efficacy

11.15.6. Product Profile

11.16. GB226/APL-501: Genor Biopharma /Apollomics (Previously CBT Pharmaceuticals)

11.16.1. Product Description

11.16.2. Other Development Activities

11.16.3. Clinical Development

11.16.4. Clinical Trials Information

11.16.5. Product Profile

11.17. Camsirubicin: Monopar Therapeutics /Gem Pharmaceuticals

11.17.1. Product Description

11.17.2. Other Development Activities

11.17.3. Clinical Development

11.17.4. Clinical Trials Information

11.17.5. Safety and Efficacy

11.17.6. Product Profile

11.18. LTX-315: Lytix Biopharma

11.18.1. Product Description

11.18.2. Other Development Activities

11.18.3. Clinical Development

11.18.4. Clinical Trials Information

11.18.5. Safety and Efficacy

11.18.6. Product Profile

11.19. Abemaciclib (LY2835219): Eli Lilly and Company

11.19.1. Product Description

11.19.2. Other Development Activities

11.19.3. Clinical Development

11.19.4. Clinical Trials Information

11.19.5. Safety and Efficacy

11.19.6. Product Profile

11.20. Pembrolizumab: Merck Sharp & Dohme Corp.

11.20.1. Product Description

11.20.2. Other Development Activities

11.20.3. Clinical Development

11.20.4. Clinical Trials Information

11.20.5. Safety and Efficacy

11.20.6. Product Profile

11.21. Crizotinib (PF-02341066): Pfizer

11.21.1. Product Description

11.21.2. Other Development Activities

11.21.3. Clinical Development

11.21.4. Clinical Trials Information

11.21.5. Safety and Efficacy

11.21.6. Product Profile

11.22. ABI-009: Aadi Bioscience

11.22.1. Product Description

11.22.2. Other Development Activities

11.22.3. Clinical Development

11.22.4. Clinical Trials Information

11.22.5. Safety and Efficacy

11.22.6. Product Profile

11.23. Nivolumab: Bristol-Myers Squibb

11.23.1. Product Description

11.23.2. Other Development Activities

11.23.3. Clinical Development

11.23.4. Clinical Trials Information

11.23.5. Safety and Efficacy

11.23.6. Product Profile

11.24. Sorafenib Tosylate: Bayer

11.24.1. Product Description

11.24.2. Clinical Development

11.24.3. Clinical Trials Information

11.24.4. Safety and Efficacy

11.24.5. Product Profile

11.25. Doxorubicin with AGEN1884 and AGEN2034: Agenus

11.25.1. Product Description

11.25.2. Clinical Development

11.25.3. Clinical Trials Information

11.25.4. Product Profile

11.26. Apatinib Mesylate (In Combination with Doxorubicin and Ifosfamide: Jiangsu HengRui Medicine

11.26.1. Product Description

11.26.2. Clinical Development

11.26.3. Clinical Trials Information

11.26.4. Product Profile

11.27. Atezolizumab: Roche Pharma AG

11.27.1. Product Description

11.27.2. Clinical Development

11.27.3. Clinical Trials Information

11.27.4. Product Profile

11.28. Spartalizumab (PDR001): Novartis Pharmaceuticals

11.28.1. Product Description

11.28.2. Other Development Activities

11.28.3. Clinical Development

11.28.4. Clinical Trials Information

11.28.5. Product Profile

11.29. Iclusig (Ponatinib): Takeda

11.29.1. Product Description

11.29.2. Other Development Activities

11.29.3. Clinical Development

11.29.4. Clinical Trials Information

11.29.5. Safety and Efficacy

11.29.6. Product Profile

11.30. Temozolomide (Temodar): Merck

11.30.1. Product Description

11.30.2. Other Developmental Activities:

11.30.3. Clinical Development

11.30.4. Clinical trial information

11.30.5. Product Profile

11.31. Cabozantinib: Exelixis

11.31.1. Product Description

11.31.2. Other Developmental Activities:

11.31.3. Clinical Development

11.31.4. Clinical trial information

11.31.5. Safety and Efficacy

11.31.6. Product Profile

11.32. Avelumab: Merck KGaA

11.32.1. Product Description

11.32.2. Other Developmental Activities:

11.32.3. Clinical Development

11.32.4. Clinical trial information

11.32.5. Product Profile

Phase I/II Emerging Molecules

11.33. Lenvatinib (In Combination with Everolimus): Eisai

11.33.1. Product Description

11.33.2. Other Development Activities

11.33.3. Clinical Development

11.33.4. Clinical Trials Information

11.33.5. Product Profile

11.34. SRA737: Sierra Oncology

11.34.1. Product Description

11.34.2. Other Development Activities

11.34.3. Clinical Development

11.34.4. Clinical Trials Information

11.34.5. Safety and Efficacy

11.34.6. Product Profile

11.35. Nab-paclitaxel: Celgene

11.35.1. Product Description

11.35.2. Other Developmental Activities

11.35.3. Clinical Development

11.35.4. Clinical Trials Information

11.35.5. Safety and Efficacy

11.35.6. Product Profile

11.36. Afatinib: Boehringer Ingelheim

11.36.1. Product Description

11.36.2. Other Development Activities

11.36.3. Clinical Development

11.36.4. Clinical Trials Information

11.36.5. Safety and Efficacy

11.36.6. Product Profile

11.37. IMCnyeso (GSK01): GlaxoSmithKline/Immunocore

11.37.1. Product Description

11.37.2. Other Development Activities

11.37.3. Clinical Development

11.37.4. Clinical Trials Information

11.37.5. Product Profile

11.38. CAR-T/TCR-T Cell Immunotherapy: Shenzhen BinDeBio

11.38.1. Product Description

11.38.2. Other Development Activities

11.38.3. Clinical Development

11.38.4. Clinical Trials Information

11.38.5. Product Profile

11.39. Epirubicin Micelle (NC-6300; K-912): NanoCarrier

11.39.1. Product Description

11.39.2. Other Development Activities

11.39.3. Clinical Development

11.39.4. Clinical Trials Information

11.39.5. Safety and Efficacy

11.39.6. Product Profile

11.40. Copanlisib (BAY806946): Bayer

11.40.1. Product Description

11.40.2. Other Developmental Activities

11.40.3. Clinical Development

11.40.4. Clinical Trials Information

11.40.5. Product Profile

11.41. PLX9486: Plexxikon

11.41.1. Product Description

11.41.2. Clinical Development

11.41.3. Clinical Trials Information

11.41.4. Safety and Efficacy

11.41.5. Product Profile

11.42. BA3021: BioAtla

11.42.1. Product Description

11.42.2. Other Developmental Activities

11.42.3. Clinical Development

11.42.4. Clinical Trials Information

11.42.5. Product Profile

11.43. Tinostamustine (EDO-S101): Mundipharma-EDO GmbH

11.43.1. Product Description

11.43.2. Other Developmental Activities

11.43.3. Clinical Development

11.43.4. Clinical Trials Information

11.43.5. Safety and Efficacy

11.43.6. Product Profile

11.44. TBI-1301 (NY-ESO-1 T cell Receptor Gene Transduced Autologous T Lymphocytes): Takara Bio.

11.44.1. Product Description

11.44.2. Other Developmental Activities

11.44.3. Clinical Development

11.44.4. Clinical Trials Information

11.44.5. Safety and Efficacy

11.44.6. Product Profile

11.45. Ramucirumab (LY3009806): Eli Lilly and Company

11.45.1. Product Description

11.45.2. Clinical Development

11.45.3. Clinical Trials Information

11.45.4. Product Profile

11.46. TB-403: Oncurious NV

11.46.1. Product Description

11.46.2. Other Developmental Activities

11.46.3. Clinical Development

11.46.4. Clinical Trials Information

11.46.5. Product Profile

11.47. TLC178: Taiwan Liposome Company

11.47.1. Product Description

11.47.2. Other Development Activities

11.47.3. Clinical Development

11.47.4. Clinical Trials Information

11.47.5. Safety and Efficacy

11.47.6. Product Profile

11.48. Talimogene Laherparepvec (T-VEC): Amgen

11.48.1. Product Description

11.48.2. Other Developmental Activities

11.48.3. Clinical Development

11.48.4. Clinical Trials Information

11.48.5. Safety and Efficacy

11.48.6. Product Profile

11.49. MEK162: Array BioPharma

11.49.1. Product Description

11.49.2. Clinical Development

11.49.3. Clinical Trials Information

11.49.4. Safety and Efficacy

11.49.5. Product Profile

11.50. Neoadjuvant Durvalumab and Tremelimumab: AstraZeneca

11.50.1. Product Description

11.50.2. Clinical Development

11.50.3. Clinical Trials Information

11.50.4. Safety and Efficacy

11.50.5. Product Profile

11.51. Selpercatinib (LOXO-292): Eli Lilly/Loxo Oncology

11.51.1. Product Description

11.51.2. Other Development Activities

11.51.3. Clinical Development

11.51.4. Clinical Trials Information

11.51.5. Product Profile

12. Soft Tissue Sarcoma (STS): 7 Major Market Analysis

12.1. Key Findings

12.2. Market Size of metastatic Soft Tissue Sarcoma (STS) in the 7MM

12.3. Market Size of metastatic Soft Tissue Sarcoma (STS) by Therapies in the 7MM

13. Market Outlook: The United States

13.1. United States Market Size

13.1.1. Total market size of Soft Tissue Sarcoma (STS)*

13.1.2. Market Size of metastatic Soft Tissue Sarcoma (STS) by Therapies in the United States

14. Market Outlook: Europe

14.1. Germany

14.1.1. The total market size of Soft Tissue Sarcoma (STS)

14.1.2. Market Size of Soft Tissue Sarcoma (STS) by Therapies in Germany

14.2. France

14.2.1. Total Market size of Soft Tissue Sarcoma (STS)

14.2.2. Market Size of metastatic Soft Tissue Sarcoma (STS) by Therapies in France

14.3. Italy

14.3.1. Total Market size of Soft Tissue Sarcoma (STS)

14.3.2. Market Size of Soft Tissue Sarcoma (STS) by Therapies in Italy

14.4. Spain

14.4.1. Total Market size of metastatic Soft Tissue Sarcoma (STS)

14.4.2. Market Size of metastatic Soft Tissue Sarcoma (STS) by Therapies in Spain

14.5. United Kingdom

14.5.1. Total Market size of metastatic Soft Tissue Sarcoma (STS)

14.5.2. Market Size of metastatic Soft Tissue Sarcoma (STS) by Therapies in the United Kingdom (UK)

15. Market Outlook: Japan

15.1. Total Market size of metastatic Soft Tissue Sarcoma (STS)

15.2. Market Size of metastatic Soft Tissue Sarcoma (STS) by Therapies in Japan

15.2.1. Market Size of metastatic Soft Tissue Sarcoma (STS) by First-line of Therapies in Japan

15.2.2. Market Size of metastatic Soft Tissue Sarcoma (STS) by Second-Line & Later Line Therapies in Japan

16. Access and Reimbursement Overview of Soft-Tissue Sarcoma (STS)

17. Market Drivers

18. Market Barriers

19. SWOT Analysis

20. Appendix

20.1. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Table 1: Summary of STS Market, Epidemiology, and Key Events (2017–2030)

Table 2: The IGF System in Sarcoma Pathogenesis

Table 3: Trunk and Extremities Sarcoma Stages

Table 4: Incident Patient Population of STS in the 7MM (2017–2030)

Table 5: Total Incident Population of STS in the United States (2017–2030)

Table 6: Type-Specific Incidence of STS in the US (2017–2030)

Table 7: Stage-Specific Incidence of STS (Excluding GIST) in the United States (2017–2030)

Table 8: Total Incident Population of GIST in the United States (2017–2030)

Table 9: Stage-Specific Incidence of GIST in the United States (2017–2030)

Table 10: Total Incident Population of STS including GIST in the United States (2017–2030)

Table 11: Gender-Specific Incidence of STS in the United States (2017–2030)

Table 12: Age-Specific Incidence of STS in the United States (2017–2030)

Table 13: Incidence of STS* by Extremities (%) in the United States (2017–2030)

Table 14: Total Incident Population of STS in Germany (2017–2030)

Table 15: Gender-Specific Incidence of STS in Germany (2017–2030)

Table 16: Type-Specific Incidence of STS in Germany (2017–2030)

Table 17: Age-Specific Incidence of STS in Germany (2017–2030)

Table 18: Stage-Specific Incidence of STS in Germany (2017–2030)

Table 19: Incidence of STS by Extremities (%) in Germany (2017–2030)

Table 20: Total Incident Population of STS in France (2017–2030)

Table 21: Gender-Specific Incidence of STS in France (2017–2030)

Table 22: Type-Specific Incidence of STS in France (2017–2030)

Table 23: Age-Specific Incidence of STS in France (2017–2030)

Table 24: Stage-Specific Incidence of STS in France (2017–2030)

Table 25: Incidence of STS by Extremities (%) in France (2017–2030)

Table 26: Total Incident Population of STS in Italy (2017–2030)

Table 27: Gender-Specific Incidence of STS in Italy (2017–2030)

Table 28: Type-Specific Incidence of STS in Italy (2017–2030)

Table 29: Age-Specific Incidence of STS in Italy (2017–2030)

Table 30: Stage-Specific Incidence of STS in Italy (2017–2030)

Table 31: Incident of STS by Extremities (%) in Italy (2017–2030)

Table 32: Total Incident Population of STS in Spain (2017–2030)

Table 33: Gender-Specific Incidence of STS in Spain (2017–2030)

Table 34: Type-Specific Incidence of STS in Spain (2017–2030)

Table 35: Age-Specific Incidence of STS in Spain (2017–2030)

Table 36: Stage-Specific Incidence of STS in Spain (2017–2030)

Table 37: Incident of STS by Extremities (%) in Spain (2017–2030)

Table 38: Total Incident Population of STS in the United Kingdom (2017–2030)

Table 39: Gender-Specific Incidence of STS in the United Kingdom (2017–2030)

Table 40: Type-Specific Incidence of STS in the UK (2017–2030)

Table 41: Age-Specific Incidence of STS in the United Kingdom (2017–2030)

Table 42: Stage-Specific Incidence of STS in the United Kingdom (2017–2030)

Table 43: Incident of STS by Extremities (%) in the United Kingdom (2017–2030)

Table 44: Total Incident Population of STS in Japan (2017–2030)

Table 45: Gender-Specific Incidence of STS in Japan (2017–2030)

Table 46: Type-Specific Incidence of STS in Japan (2017–2030)

Table 47: Age-Specific Incidence of STS in Japan (2017–2030)

Table 48: Stage-Specific Incidence of STS in Japan (2017–2030)

Table 49: Incident of STS by Extremities (%) in Japan (2017–2030)

Table 50: Novel and Targeted Agents for the Treatment of Soft-Tissue Sarcomas

Table 51: levels of evidence and grades of recommendation (adapted from the Infectious Diseases Society of America- United States Public Health Service Grading System)

Table 52: Recommended dressings for neonates with EB

Table 53: Marketed Drug analysis

Table 54: Halaven, Clinical Trial Description, 2020

Table 55: Halaven; Clinical Trial Description, 2020

Table 56: Gleevec (Imatinib Mesylate), Clinical Trial Description, 2020

Table 57: Yondelis (Trabectedin), Clinical Trial Description, 2020

Table 58: Lartruvo (Olaratumab); Clinical Trial Description, 2020

Table 59: Vitrakvi, Clinical Trial Description, 2020

Table 60: Stivarga, Clinical Trial Description, 2020

Table 61: Stivarga; Clinical Trial Description, 2020

Table 62: Sutent; Clinical Trial Description, 2020

Table 63: Pazopanib, Clinical Trial Description, 2020

Table 64: Pazopanib; Clinical Trial Description, 2020

Table 65: Emerging Key cross Competition

Table 66: Emerging Key cross Competition (continued)

Table 67: Avapritinib (BLU-285), Clinical Trial Description, 2020

Table 68: Vigil, Clinical Trial Description, 2020

Table 69: Anlotinib (AL3818), Clinical Trial Description, 2020

Table 70: Selinexor, Clinical Trial Description, 2020

Table 71: Aldoxorubicin, Clinical Trial Description, 2020

Table 72: DCC-2618, Clinical Trial Description, 2020

Table 73: Fibromun (L19TNF); Clinical Trial Description, 2020

Table 74: NBTXR3, Clinical Trial Description, 2020

Table 75: Crenolanib, Clinical Trial Description, 2020

Table 76: TAS-116, Clinical Trial Description, 2020

Table 77: GSK3377794, Clinical Trial Description, 2020

Table 78: ADP-A2M4, Clinical Trial Description, 2020

Table 79: Tazemetostat; Clinical Trial Description, 2020

Table 80: AMG 337; Clinical Trial Description, 2020

Table 81: APL-501/GB226, Clinical Trial Description, 2020

Table 82: Camsirubicin, Clinical Trial Description, 2020

Table 83: LTX-315; Clinical Trial Description, 2020

Table 84: LY2835219, Clinical Trial Description, 2020

Table 85: Keytruda in combination with other drugs for soft tissue sarcoma

Table 86: Pembrolizumab, Clinical Trial Description, 2020

Table 87: Crizotinib, Clinical Trial Description, 2020

Table 88: ABI-009, Clinical Trial Description, 2020

Table 89: Combinations of Nivolumab

Table 90: Nivolumab; Clinical Trial Description, 2020

Table 91: Sorafenib Tosylate, Clinical Trial Description, 2020

Table 92: Doxorubicin with AGEN1884 and AGEN2034; Clinical Trial Description, 2020

Table 93: Apatinib Mesylate (In Combination with Doxorubicin and Ifosfamide, Clinical Trial Description, 2020

Table 94: Atezolizumab, Clinical Trial Description, 2020

Table 95: PDR001, Clinical Trial Description, 2020

Table 96: Ponatinib, Clinical Trial Description, 2020

Table 97: Lenvatinib (In combination with Everolimus), Clinical Trial Description, 2020

Table 98: SRA737, Clinical Trial Description, 2020

Table 99: Nab-paclitaxel; Clinical Trial Description, 2020

Table 100: Afatinib; Clinical Trial Description, 2020

Table 101: IMCnyeso, Clinical Trial Description, 2020

Table 102: CAR-T/TCR-T Cell Immunotherapy, Clinical Trial Description, 2020

Table 103: NC 6300, Clinical Trial Description, 2020

Table 104: Copanlisib (BAY806946); Clinical Trial Description, 2020

Table 105: PLX9486+/-PLX3397; Clinical Trial Description, 2020

Table 106: BA3021; Clinical Trial Description, 2020

Table 107: Tinostamustine (EDO-S101); Clinical Trial Description, 2020

Table 108: TBI-1301; Clinical Trial Description, 2020

Table 109: Ramucirumab (LY3009806); Clinical Trial Description, 2020

Table 110: TB-403; Clinical Trial Description, 2020

Table 111: TLC178; Clinical Trial Description, 2020

Table 112: Talimogene Laherparepvec, Clinical Trial Description, 2020

Table 113: MEK162, Clinical Trial Description, 2020

Table 114: Neoadjuvant Durvalumab and Tremelimumab, Clinical Trial Description, 2020

Table 115: LOXO-292, Clinical Trial Description, 2020

Table 116: Market size of mSTS by Region in USD Million (2017–2030)

Table 117: Market Size of metastatic STS by Therapies in the 7MM, in USD Million (2017–2030)

Table 118: United States Market Size of mSTS* in USD Million (2017–2030)

Table 119: Market Size of metastatic STS by Therapies in the United States, in USD Million (2017–2030)

Table 120: Market Size of mSTS by First-line of Therapies in the US, in USD Million (2017–2030)

Table 121: Market Size of metastatic STS by Second-line & Later Line Therapies in the US, in USD Million (2017–2030)

Table 122: Market Size of mGIST in the United States, in USD Million (2017–2030)

Table 123: United States Market Size of mSTS including GIST in USD Million (2017–2030)

Table 124: Germany Market Size of STS in USD Million (2017–2030)

Table 125: Market Size of metastatic STS by Therapies in Germany, in USD Million (2017–2030)

Table 126: Market Size of STS by First-line of Therapies in Germany, in USD Million (2017–2030)

Table 127: Market Size of metastatic STS by Second-line and later on Therapies in Germany, in USD Million (2017–2030)

Table 128: France Market Size of STS in USD Million (2017–2030)

Table 129: Market Size of mSTS by Therapies in France, in USD Million (2017–2030)

Table 130: Market Size of mSTS by First-line of Therapies in France, in USD Million (2017–2030)

Table 131: Market Size of STS by Second-line and Later Line Therapies in France, in USD Million (2017–2030)

Table 132: Italy Market Size of mSTS in USD Million (2017–2030)

Table 133: Market Size of mSTS by Therapies in Italy, in USD Million (2017–2030)

Table 134: Market Size of mSTS by First-line of Therapies in Italy, in USD Million (2017–2030)

Table 135: Market Size of STS by Second-line and Later Line Therapies in Italy, in USD Million (2017–2030)

Table 136: Spain Market Size of mSTS in USD Million (2017–2030)

Table 137: Market Size of mSTS by Therapies in Spain, in USD Million (2017–2030)

Table 138: Market Size of mSTS by First-line of Therapies in Spain, in USD Million (2017–2030)

Table 139: Market Size of STS by Second-line and Later Line Therapies in Spain, in USD Million (2017–2030)

Table 140: United Kingdom Market Size of mSTS in USD Million (2017–2030)

Table 141: Market Size of mSTS by Therapies in the United Kingdom, in USD Million (2017–2030)

Table 142: Market Size of mSTS by First-line of Therapies in the UK, in USD Million (2017–2030)

Table 143: Market Size of STS by Second-line and Later Line Therapies in the UK, in USD Million (2017–2030)

Table 144: Japan Market Size of mSTS in USD Million (2017–2030)

Table 145: Market Size of mSTS by Therapies in Japan, in USD Million (2017–2030)

Table 146: Market Size of mSTS by First-line of Therapies in Japan, in USD Million (2017–2030)

Table 147: Market Size of STS by Second-line and Later Line Therapies in Japan, in USD Million (2017–2030)

Figure 1: Common Types of Soft-Tissue Sarcomas (STS)

Figure 2: AngiosarcomaFigure 3:Dermatofibrosarcoma protuberans (DFSP)

Figure 4: Several Growth Factor Signals Activate Cell Membrane Receptor Tyrosine Kinases Leading to Activation of Downstream Interacting Signal Transduction Pathways (PI3K/AKT, RAF/MAPK, and mTOR)

Figure 5: Grade Numbers of Soft-Tissue Sarcoma (STS)

Figure 6: Diagnosis of Soft-Tissue Sarcoma

Figure 7: Imaging Tests for Soft-Tissue Sarcoma (STS)

Figure 8: Incidence of STS in the 7MM (2017–2030)

Figure 9: Total Incident Cases of STS in the United States (2017–2030)

Figure 10: Type-Specific Incidence of STS in the United States (2017–2030)

Figure 11: Stage-Specific Incidence of STS (Excluding GIST) in the United States (2017–2030)

Figure 12: Total Incident Cases of GIST in the United States (2017–2030)

Figure 13: Stage-Specific Incidence of GIST in the United States (2017–2030)

Figure 14: Total Incident Cases of STS including GIST in the United States (2017–2030)

Figure 15: Gender-Specific Incidence of STS in the United States (2017–2030)

Figure 16: Age-Specific Incidence of STS in the United States (2017–2030)

Figure 17: Incidence of STS* by Extremities (%) in the United States (2017–2030)

Figure 18: Total Incident Cases of STS in Germany (2017–2030)

Figure 19: Gender-Specific Incidence of STS in Germany (2017–2030)

Figure 20: Type-Specific Incident of STS in Germany (2017–2030)

Figure 21: Age-Specific Incidence of STS in Germany (2017–2030)

Figure 22: Stage-Specific Incidence of STS in Germany (2017–2030)

Figure 23: Incidence of STS by Extremities (%) in Germany (2017–2030)

Figure 24: Total Incident Cases of STS in France (2017–2030)

Figure 25: Gender-Specific Incidence of STS in France (2017–2030)

Figure 26: Type-Specific Incident of STS in France (2017–2030)

Figure 27: Age-Specific Incidence of STS in France (2017–2030)

Figure 28: Stage-Specific of STS in France (2017–2030)

Figure 29: Incidence of STS by Extremities (%) in France (2017–2030)

Figure 30: Total Incident Cases of STS in Italy (2017–2030)

Figure 31: Gender-Specific Incidence of STS in Italy (2017–2030)

Figure 32: Type-Specific Incident of STS in Italy (2017–2030)

Figure 33: Age-Specific Incidence of STS in Italy (2017–2030)

Figure 34: Stage-Specific Incidence of STS in Italy (2017–2030)

Figure 35: Incident of STS by Extremities (%) in Italy (2017–2030)

Figure 36: Total Incident Cases of STS in Spain (2017–2030)

Figure 37: Gender-Specific Incidence of STS in Spain (2017–2030)

Figure 38: Type-Specific Incident of STS in Spain (2017–2030)

Figure 39: Age-Specific Incidence of STS in Spain (2017–2030)

Figure 40: Stage-Specific Incidence of STS in Spain (2017–2030)

Figure 41: Incident of STS by Extremities (%) in Spain (2017–2030)

Figure 42: Total Incident Cases of STS in the United Kingdom (2017–2030)

Figure 43: Gender-Specific Incidence of STS in the United Kingdom (2017–2030)

Figure 44: Type-Specific Incident of STS in the United Kingdom (2017–2030)

Figure 45: Age-Specific Incidence of STS in the United Kingdom (2017–2030)

Figure 46: Stage-Specific Incidence of STS in the United Kingdom (2017–2030)

Figure 47: Incident of STS by Extremities (%) in the United Kingdom (2017–2030)

Figure 48: Total Incident Cases of STS in Japan (2017–2030)

Figure 49: Gender-Specific Incidence of STS in Japan (2017–2030)

Figure 50: Type-Specific Incident of STS in Japan (2017–2030)

Figure 51: Age-Specific Incidence of STS in Japan (2017–2030)

Figure 52: Stage-Specific Incidence of STS in Japan (2017–2030)

Figure 53: Incident of STS by Extremities (%) in Japan (2017–2030)

Figure 54: Management of Soft Tissue Sarcoma

Figure 55: Management of localized, clinically resectable STS

Figure 56: Management of advanced/metastatic, clinically unresectable STS

Figure 57: Treatment Algorithm of Advanced Liposarcoma

Figure 58: Treatment Algorithm of Advanced Soft Tissue Sarcoma

Figure 59: Treatment Algorithm of Advanced Leiomyosarcoma

Figure 60: Therapy algorithm for Undifferentiated Pleomorphic/Non-classifiable Sarcoma

Figure 61: Therapy algorithm for Advanced Angiosarcoma

Figure 62: Therapy algorithm for Advanced Synovial Sarcoma

Figure 63: Unmet Needs of Gastroparesis

Figure 64: Market size of metastatic Soft Tissue Sarcoma (STS) by Region in USD Million (2017–2030)

Figure 65: Market Size of mSTS by Therapies in 7MM, in USD Million (2017–2030)

Figure 66: United States Market Size of STS in USD Million (2017–2030)

Figure 67: Market Size of mSTS by Therapies in the United States in USD Million (2017–2030)

Figure 68: Market Size of metastatic STS by First-line of Therapies in the US, in USD Million (2017–2030)

Figure 69: Market Size of metastatic STS by Second-line and Later Line Therapies in the US, in USD Million (2017–2030)

Figure 70: Market Size of mGIST in the United States in USD Million (2017–2030)

Figure 71: United States Market Size of mSTS including GIST in USD Million (2017–2030)

Figure 72: Germany Market Size of STS in USD Million (2017–2030)

Figure 73: Market Size of STS by Therapies in Germany in USD Million (2017–2030)

Figure 74: Market Size of metastatic STS by First-line of Therapies in Germany, in USD Million (2017–2030)

Figure 75: Market Size of metastatic STS by Second-line and later on Therapies in Germany, in USD Million (2017–2030)

Figure 76: France Market Size of metastatic STS in USD Million (2017–2030)

Figure 77: Market Size of mSTS by Therapies in France in USD Million (2017–2030)

Figure 78: Market Size of mSTS by First-line of Therapies in France, in USD Million (2017–2030)

Figure 79: Market Size of mSTS by Second-line & Later Line Therapies in France, in USD Million (2018–2030)

Figure 80: Italy Market Size of mSTS in USD Million (2017–2030)

Figure 81: Market Size of mSTS by Therapies in Italy in USD Million (2017–2030)

Figure 82: Market Size of mSTS by First-line of Therapies in Italy, in USD Million (2017–2030)

Figure 83: Market Size of mSTS by Second-line & Later Line Therapies in Italy, in USD Million (2017–2030)

Figure 84: Spain Market Size of mSTS in USD Million (2017–2030)

Figure 85: Market Size of mSTS by Therapies in Spain in USD Million (2017–2030)

Figure 86: Market Size of mSTS by First-line of Therapies in Spain, in USD Million (2017–2030)

Figure 87: Market Size of mSTS by Second-line & Later Line Therapies in Spain, in USD Million (2017–2030)

Figure 88: United Kingdom Market Size of mSTS in USD Million (2017–2030)

Figure 89: Market Size of mSTS by Therapies in the UK in USD Million (2017–2030)

Figure 90: Market Size of mSTS by First-line of Therapies in the UK, in USD Million (2017–2030)

Figure 91: Market Size of mSTS by Second-line & Later Line Therapies in the UK, in USD Million (2017–2030)

Figure 92: Japan Market Size of mSTS in USD Million (2017–2030)

Figure 93: Market Size of mSTS by Therapies in Japan in USD Million (2017–2030)

Figure 94: Market Size of mSTS by First-line of Therapies in Japan, in USD Million (2017–2030)

Figure 95: Market Size of STS by Second-line & Later Line Therapies in Japan, in USD Million (2017–2030)

Figure 96: Factors affecting treatment of Soft Tissue Sarcoma

Figure 97: Market Drivers

Figure 98:Market Barriers

Figure 99:Soft Tissue Sarcoma—SWOT analysis (Overall)

Figure 100: Anlotinib for soft tissue sarcoma—SWOT analysis (Drug Specific)

Figure 101: Fibromun for soft tissue sarcoma—SWOT analysis (Drug Specific)

• Blueprint Medicines Corporation

• Gradalis

• Advenchen Laboratories

• Karyopharm Therapeutics

• CytRx

• Deciphera Pharmaceuticals

• Philogen S.p.A

• GlaxoSmithKline

• Adaptimmune

• Epizyme, Inc.

• NantPharma

• Genor Biopharma Co., Ltd/.Apollomics, Inc.

• Gem Pharmaceuticals

• Lytix Biopharma AS

• NanoCarrier Co., Ltd.

• Eli Lilly and Company

• Merck Sharp & Dohme Corp.

• Pfizer

• Aadi Bioscience

• Bristol-Myers Squibb/Ono Pharmaceuticals

• Sierra Oncology

• Nanobiotix

• Bayer

• Eisai

• Novartis

• Pfizer

• Janssen Biotech

• GSK

• Bayers

• Pfizer

• Eli Lilly

• Bayer, Loxo Oncology

  • Tags:
  • Soft Tissue Sarcoma market
  • Soft Tissue Sarcoma market research
  • Soft Tissue Sarcoma market insight
  • Soft Tissue Sarcoma market trends
  • Soft Tissue Sarcoma market forecast
  • Soft Tissue Sarcoma market share
  • Soft Tissue Sarcoma pipeline drugs
  • Soft Tissue Sarcoma treatment algor...
  • Soft Tissue Sarcoma drugs
  • Soft Tissue Sarcoma sales forecasti...
  • Soft Tissue Sarcoma market size
  • Soft Tissue Sarcoma disease
  • Soft Tissue Sarcoma epidemiology
  • Soft Tissue Sarcoma

Forward to Friend

Need A Quote